{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:56:54Z","timestamp":1779173814257,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Forensic Toxicol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Quantification of olanzapine (OLZ) and its metabolites such as<jats:italic> N<\/jats:italic>-desmethylolanzapine (DM-O), 2-hydroxymethylolanzapine (2H-O) and olanzapine <jats:italic>N<\/jats:italic>-oxide (NO-O) in five kinds of human body fluids including whole blood by liquid chromatography (LC)\u2013tandem mass spectrometry (MS\/MS) has been presented; the quantification methods were carefully devised and validated using the matrix-matched calibration and standard addition methods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>OLZ and its three metabolites were extracted from 40 \u03bcL each of body fluids by two-step liquid\u2013liquid separations. The samples and reagents were pre-cooled in a container filled with ice for the extraction because of the thermal instability of OLZ and its three metabolites especially in whole blood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The limits of quantification (LOQs) of OLZ and 2H-O were 0.05\u00a0ng\/mL and those of DM-O and NO-O were 0.15\u00a0ng\/mL in whole blood and urine, respectively. The concentrations of OLZ and its metabolites in heart whole blood, pericardial fluid, stomach contents, bile and urine were determined for two cadavers and those in whole blood and urine for the other two cadavers. The reduction from NO-O to OLZ was observed at 25\u00a0\u2103 in whole blood in vitro.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>To our knowledge, this is the first report on the quantification of metabolites of olanzapine in the authentic human body fluids by LC\u2013MS\/MS as well as on the confirmation of in vitro reduction from NO-O to OLZ in whole blood that seems to have induced the quick decrease of NO-O.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11419-023-00662-0","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T12:23:43Z","timestamp":1680611023000},"page":"318-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quantification of olanzapine and its three metabolites by liquid chromatography\u2013tandem mass spectrometry in human body fluids obtained from four deceased, and confirmation of the reduction from olanzapine N-oxide to olanzapine in whole blood in vitro"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9433-9034","authenticated-orcid":false,"given":"Hideki","family":"Nozawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koutaro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotomo","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kitamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minako","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"662_CR1","first-page":"658","volume":"276","author":"BJ Ring","year":"1996","unstructured":"Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA (1996) Identification of human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276:658\u2013666 ((PMID: 8632334))","journal-title":"J Pharmacol Exp Ther"},{"key":"662_CR2","first-page":"81","volume":"25","author":"K Kassahun","year":"1997","unstructured":"Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L (1997) Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Disp 25:81\u201393 ((PMID: 9010634))","journal-title":"Drug Metab Disp"},{"key":"662_CR3","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/(SICI)1096-9888(199812)33:12<1237::AID-JMS742>3.0.CO;2-F","volume":"33","author":"AT Murphy","year":"1998","unstructured":"Murphy AT, Lake BG, Bernstein JR, Franklin RB, Gillespie TA (1998) Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography\/tandem mass spectrometry. J Mass Spectrom 33:1237\u20131245. https:\/\/doi.org\/10.1002\/(SICI)1096-9888(199812)33:12%3c1237::AID-JMS742%3e3.0.CO;2-F","journal-title":"J Mass Spectrom"},{"key":"662_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cca.2013.11.024","volume":"429","author":"L Patteet","year":"2014","unstructured":"Patteet L, Maudens KE, Sabbe B, Morrens M, De Doncker M, Neels H (2014) High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Clin Chim Acta 429:51\u201358. https:\/\/doi.org\/10.1016\/j.cca.2013.11.024","journal-title":"Clin Chim Acta"},{"key":"662_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/bmc.3329","volume":"29","author":"HG Lou","year":"2015","unstructured":"Lou HG, Ruan ZR, Jiang B, Chen JL (2015) Simultaneous quantification of olanzapine and its metabolite N-desmethylolanzapine in human plasma by liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. Biomed Chromatogr 29:671\u2013678. https:\/\/doi.org\/10.1002\/bmc.3329","journal-title":"Biomed Chromatogr"},{"key":"662_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24020310","author":"LGM Beloti","year":"2019","unstructured":"Beloti LGM, Miranda LFC, Queiroz MEC (2019) Butyl methacrylate-co-ethylene glycol dimethacrylate monolith for online in-tube SPME-UHPLC-MS\/MS to determine chlorpromazine, clozapine, quetiapine, olanzapine, and their metabolites in plasma samples. Molecules. https:\/\/doi.org\/10.3390\/molecules24020310","journal-title":"Molecules"},{"key":"662_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jchromb.2012.09.009","volume":"907","author":"R U\u0159inovsk\u00e1","year":"2012","unstructured":"U\u0159inovsk\u00e1 R, Brozmanov\u00e1 H, \u0160i\u0161t\u00edk P, \u0160ilh\u00e1n P, Kac\u00ed\u0159ov\u00e1 I, Lemr K, Grundmann M (2012) Liquid chromatography-tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum. J Chromatogr B 907:101\u2013107. https:\/\/doi.org\/10.1016\/j.jchromb.2012.09.009","journal-title":"J Chromatogr B"},{"key":"662_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/tpj.2012.47","volume":"13","author":"MM S\u00f6derberg","year":"2013","unstructured":"S\u00f6derberg MM, Haslemo T, Molden E, Dahl M-L (2013) Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. Pharmacogenomics J 13:544\u2013550. https:\/\/doi.org\/10.1038\/tpj.2012.47","journal-title":"Pharmacogenomics J"},{"key":"662_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s0378-4347(01)00548-5","volume":"767","author":"M Berna","year":"2002","unstructured":"Berna M, Ackermann B, Ruterbories K, Glass S (2002) Determination of olanzapine in human blood by liquid chromatography\u2013tandem mass spectrometry. J Chromatogr B 767:163\u2013168. https:\/\/doi.org\/10.1016\/s0378-4347(01)00548-5","journal-title":"J Chromatogr B"},{"key":"662_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.forsciint.2011.02.022","volume":"215","author":"E Saar","year":"2012","unstructured":"Saar E, Gerostamoulos D, Drummer OH, Beyer J (2012) Assessment of the stability of 30 antipsychotic drugs in stored blood specimens. Forensic Sci Int 215:152\u2013158. https:\/\/doi.org\/10.1016\/j.forsciint.2011.02.022","journal-title":"Forensic Sci Int"},{"key":"662_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.legalmed.2014.05.001","volume":"16","author":"A Wurita","year":"2014","unstructured":"Wurita A, Hasegawa K, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Suzuki O, Watanabe K (2014) Postmortem distribution of \u03b1-pyrrolidinobutiophenone in body fluids and solid tissues of a human cadaver. Leg Med 16:241\u2013246. https:\/\/doi.org\/10.1016\/j.legalmed.2014.05.001","journal-title":"Leg Med"},{"key":"662_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s11419-019-00470-5","volume":"37","author":"A Wurita","year":"2019","unstructured":"Wurita A, Hasegawa K, Konno K, Hashimoto K, Gonmori K, Minakata K, Nozawa H, Yamagishi I, Watanabe K, Suzuki O (2019) Quantification of clitidine in caps and stems of poisonous mushroom Paralepistopsis acromelalga by hydrophilic interaction liquid chromatography\u2013tandem mass spectrometry. Forensic Toxicol 37:378\u2013386. https:\/\/doi.org\/10.1007\/s11419-019-00470-5","journal-title":"Forensic Toxicol"},{"key":"662_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11419-021-00585-8(openaccessarticle)","volume":"39","author":"K Hasegawa","year":"2021","unstructured":"Hasegawa K, Minakata K, Suzuki M, Suzuki O (2021) The standard addition method and its validation in forensic toxicology. Forensic Toxicol 39:311\u2013333. https:\/\/doi.org\/10.1007\/s11419-021-00585-8(openaccessarticle)","journal-title":"Forensic Toxicol"},{"key":"662_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13054-020-02915-5(openaccessarticle)","volume":"24","author":"M Schulz","year":"2020","unstructured":"Schulz M, Schmoldt A, Andresen-Streichert H, Iwersen-Bergmann S (2020) Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care 24:195. https:\/\/doi.org\/10.1186\/s13054-020-02915-5(openaccessarticle)","journal-title":"Crit Care"},{"key":"662_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.forsciint.2006.05.021","volume":"165","author":"FT Peters","year":"2007","unstructured":"Peters FT, Drummer OH, Musshoff F (2007) Validation of new methods. Forensic Sci Int 165:216\u2013224. https:\/\/doi.org\/10.1016\/j.forsciint.2006.05.021","journal-title":"Forensic Sci Int"},{"key":"662_CR16","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/0006-291X(68)90414-2","volume":"33","author":"MH Bickel","year":"1968","unstructured":"Bickel MH, Weder HJ, Aebi H (1968) Metabolic interconversions between imipramine, its N-oxide, and its desmethyl derivative in rat tissues in vitro. Biochem Biophys Res Comm 33:1012\u20131018. https:\/\/doi.org\/10.1016\/0006-291X(68)90414-2","journal-title":"Biochem Biophys Res Comm"},{"key":"662_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/0003-9861(72)90114-2(openaccessarticle)","volume":"148","author":"MH Bickel","year":"1972","unstructured":"Bickel MH (1972) Liver metabolic reactions: tertiary amine N-dealkylation, tertiary amine N-oxidation, N-oxide reduction, and N-oxide N-dealkylation I. Tricyclic tertiary amine drugs. Arch Biochem Biophys 148:54\u201362. https:\/\/doi.org\/10.1016\/0003-9861(72)90114-2(openaccessarticle)","journal-title":"Arch Biochem Biophys"},{"key":"662_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0960-894X(96)00567-7","volume":"7","author":"DO Calligaro","year":"1997","unstructured":"Calligaro DO, Fairhurst J, Hotten TM, Moore NA, Tupper DE (1997) The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053). Bioorg Med Chem Lett 7:25\u201330. https:\/\/doi.org\/10.1016\/S0960-894X(96)00567-7","journal-title":"Bioorg Med Chem Lett"},{"key":"662_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1570-0232(2)00164-2","volume":"773","author":"LJ Dusci","year":"2002","unstructured":"Dusci LJ, Hackett LP, Fellows LM, Ilett KF (2002) Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. J Chromatogr B 773:191\u2013197. https:\/\/doi.org\/10.1016\/S1570-0232(2)00164-2","journal-title":"J Chromatogr B"}],"container-title":["Forensic Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-023-00662-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11419-023-00662-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-023-00662-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T15:57:28Z","timestamp":1688054248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11419-023-00662-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1007\/s11419-023-00662-0","relation":{},"ISSN":["1860-8965","1860-8973"],"issn-type":[{"value":"1860-8965","type":"print"},{"value":"1860-8973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"30 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or other relations that could lead to a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all participants (coauthors) included in this study, who supplied about 15\u00a0mL each of blood and\/or 40\u00a0mL each of urine for use as blank samples. The analysis of toxic substances in the present four deceased was permitted by judicial authorities and supported by official documentation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}